Viking Therapeutics Stock Consolidates as Market Awaits Next Catalyst

Shares of Viking Therapeutics are currently trading within a narrow band between $35 and $36, continuing a period of consolidation that has characterized December’s trading activity. Following significant clinical progress for its obesity candidate VK2735, the market appears to be taking a breather. The company’s ability to deliver the next set of trial data promptly is now a key focus for investors.

From a financial perspective, Viking Therapeutics is well-positioned. The company concluded the third quarter with approximately $700 to $714 million in liquid assets. This robust cash position is critical for funding its costly Phase 3 programs without an immediate need for further capital raises in the near term.

Market Read more...